Trial Profile
The pharmacokinetics and pharmacodynamics of subcutaneously administered vessel dilator peptide in stable patients with chronic heart failure and moderate renal impairment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Atrial natriuretic factor (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Madeleine Pharmaceuticals
- 31 May 2012 New trial record